Chemosensitisation of malignant melanoma by BCL2 antisense therapy
Top Cited Papers
- 1 November 2000
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 356 (9243), 1728-1733
- https://doi.org/10.1016/s0140-6736(00)03207-4
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2000
- Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 OligodeoxynucleotidesJNCI Journal of the National Cancer Institute, 2000
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant MelanomaJournal of Clinical Oncology, 2000
- Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell linesMelanoma Research, 1998
- BCL-2 antisense therapy in patients with non-Hodgkin lymphomaThe Lancet, 1997
- Bcl-2 expression in malignant melanoma and its prognostic significanceEuropean Journal of Surgical Oncology, 1996
- Massive Cell Death of Immature Hematopoietic Cells and Neurons in Bcl-x-Deficient MiceScience, 1995
- bcl-2 Protein Expression in Cutaneous Malignant Melanoma and Benign Melanocytic NeviThe American Journal of Dermatopathology, 1995
- Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hairCell, 1993
- BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.Proceedings of the National Academy of Sciences, 1991